

Immune correlates of HIV exposure without infection in foreskins of men from Rakai, Uganda

JL Prodger^{1,8}, T Hirbod^{2,8}, G Kigozi³, F Nalugoda³, SJ Reynolds^{3,4,5}, R Galiwango³, K Shahabi¹, D Serwadda^{3,6}, MJ Wawer^{3,7}, RH Gray^{3,7}, R Kaul¹ and the Rakai Genital Immunology Research Group^{3,9}

Human immunodeficiency virus (HIV) susceptibility is heterogenous, with some HIV-exposed but seronegative (HESN) individuals remaining uninfected despite repeated exposure. Previous studies in the cervix have shown that reduced HIV susceptibility may be mediated by immune alterations in the genital mucosa. However, immune correlates of HIV exposure without infection have not been investigated in the foreskin. We collected sub-preputial swabs and foreskin tissue from HESN ($n = 20$) and unexposed control ($n = 57$) men undergoing elective circumcision. Blinded investigators assayed swabs for HIV-neutralizing IgA, innate antimicrobial peptides, and cytokine levels. Functional T-cell subsets from foreskin tissue were assessed by flow cytometry. HESN foreskins had elevated α -defensins (3,027 vs. 1,795 pg ml⁻¹, $P = 0.011$) and HIV-neutralizing IgA (50.0 vs. 13.5% of men, $P = 0.019$). Foreskin tissue from HESN men contained a higher density of CD3 T cells (151.9 vs. 69.9 cells mm⁻², $P = 0.018$), but a lower proportion of these was Th17 cells (6.12 vs. 8.04% of CD4 T cells, $P = 0.007$), and fewer produced tumor necrosis factor α (TNF α) (34.3 vs. 41.8% of CD4 T cells, $P = 0.037$; 36.9 vs. 45.7% of CD8 T cells, $P = 0.004$). A decrease in the relative abundance of susceptible CD4 T cells and local TNF α production, in combination with HIV-neutralizing IgA and α -defensins, may represent a protective immune milieu at a site of HIV exposure.

INTRODUCTION

Human immunodeficiency virus 1 (HIV) is primarily transmitted through unprotected sex. Despite the high global prevalence of HIV, transmission of the virus during insertive vaginal sex is both relatively inefficient and heterogenous, with the estimated per-contact risk of female-to-male transmission ranging from 1/200 to 1/2,000.¹ To rationally design new tools to prevent HIV transmission, we need to understand the mucosal determinants of transmission. Individuals who are regularly HIV-exposed but seronegative (HESN) may provide important insights into the mucosal immune correlates of resistance to HIV infection.

A number of previous studies have examined these immune parameters in HESN individuals exposed to HIV through sero-discordant sexual relationships or commercial sex work. Mucosal secretions (cervical and salivary) from HESN

individuals contain higher levels of several antimicrobial peptides and C-C chemokines that have been shown to have antiviral or HIV-neutralizing capacity *in vitro*. Upregulated antimicrobial proteins include cathelicidin LL-37,^{2,3} α -defensins (human neutrophil peptides 1–3, HNP1–3),^{2,3} β -defensins (human β -defensin 2 (HBD2)),^{4,5} protease inhibitors^{6–8} (secretory leukocyte protease inhibitor (SLPI) and trappin-2/Elafin), and interferon- α (IFN α).⁹ Upregulated C-C chemokines include macrophage inflammatory protein-1 α (MIP-1 α),¹⁰ monocyte chemoattractant protein-1 (MCP-1),¹⁰ and regulated upon activation normal T-cell expressed and secreted (RANTES).^{9,11} Furthermore, cervico-vaginal secretions and saliva from HESN individuals may contain HIV-neutralizing IgA,^{12,13} which was associated with a reduced risk of HIV acquisition in a prospective study.¹⁴

¹Department of Medicine, University of Toronto, Toronto, Ontario, Canada. ²Department of Medicine, Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. ³Rakai Health Sciences Program, Kalisizo, Uganda. ⁴Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. ⁵Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. ⁶Institute of Public Health, Makerere University, Kampala, Uganda and ⁷Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Correspondence: JL Prodger (jessica.prodger@utoronto.ca)

⁸These authors contributed equally to this article and are co-first authors.

⁹Rakai Genital Immunology Group Members: Kighoma Nehemiah, Tumuramy Denis, Mbagiira Emma, Kubaawo John-Bosco, Isabirye Yahaya, Mulema Patrick, Teba James, Atukunda Boru, Mayengo Herbert, Nakafeero Mary, Mugamba Stephen, Nakyeyune Mary, Anyokorit Margaret, Male Deo, Kayiwa Dan, Kalibbala Sarah, Lubyayi Lawrence, Otobi Ouma Joseph, Kakanga Moses, Okech John Baptist, Okello Grace, Aluma Gerald, Ssebugenyi Ivan, Balikudembe Ambrose.

Received 12 July 2013; revised 21 August 2013; accepted 9 September 2013; published online 23 October 2013. doi:10.1038/mi.2013.83

These data suggest that higher mucosal levels of certain innate/adaptive immune molecules may provide protection against HIV acquisition. However, some mucosal immune factors that neutralize HIV *in vitro* also activate or recruit HIV target cells, thereby negating any protective neutralizing effect of the peptide, or even increasing HIV susceptibility *in vivo*, as appears to be the case for LL-37 and α -defensins.^{3,15,16} Indeed, there is evidence to suggest that reduced immune activation at the site of HIV exposure may correlate with resistance to infection. Cervical secretions from HESN women in Nairobi contain lower levels of C-X-C chemokines and the pro-inflammatory cytokine interleukin-1 α (IL-1 α) as compared with new (non-HESN) commercial sex works.⁶ Furthermore, T cells from the blood and genital tract of HESN women have increased regulatory T cells (Tregs),^{17,18} lower CD4 T-cell expression of the activation markers HLA-DR^{19,20} and CD38,^{20,21} and reduced production of the inflammatory cytokines IL-17, IL-22, IL-1 β , IL-6, and tumor necrosis factor α (TNF α).^{22,23} Taken together, these studies suggest that relative resistance to HIV infection may require a delicate balance between the levels of antimicrobial peptides in genital secretions and of activated/highly susceptible target cells of the mucosa.

Randomized trials of male circumcision have demonstrated that the foreskin is the main site of HIV acquisition in heterosexual men,^{24–26} underlining the need to better characterize the immune correlates of HIV susceptibility in this anatomic site. Compared with blood, T cells in the foreskin produce more cytokines, express more CCR5, and are enriched for highly HIV-susceptible Th17 cells.²⁷ Additionally, foreskin tissue has been shown to produce several soluble peptides that have *in vitro* antiviral activity.¹⁶ Therefore, we performed an investigator-blinded study to define the immune correlates of reduced HIV susceptibility in the foreskins of HESN men from Rakai, Uganda.

RESULTS

Participant characteristics

Participants were recruited from a longstanding community cohort in Rakai, Uganda.²⁸ HESN men ($n = 20$; see Materials and methods for definition) had been in a primary sexual relationship with an HIV-infected woman for a median of 5 years (range, 1–10 years; see **Table 1**). HESN men reported using condoms either “sometimes” (30%) or “never” (70%), and the median plasma viral load of the HIV-seropositive female partner was 3.74 log₁₀ RNA copies per ml (range 1.62–5.22; **Table 1**). All HESN participants were HIV PCR negative at the time of the study. HESN men and HIV-unexposed control men did not differ in terms of age, condom use, or the number of sexual partners in the last year. However, HESN men had a higher herpes simplex virus 2 (HSV-2) seroprevalence than unexposed controls (70 vs. 31.5%, $P = 0.004$) and were more likely to report concurrent sexual relationships (3/20 vs. 0/57, $P = 0.016$); therefore, multivariate linear regression was used to control for HSV-2 status and concurrent sexual relationships in all subsequent analyses, and only adjusted

P -values are reported. Of note, while concurrent sexual relationships were not associated ($P < 0.1$) with any of the immunological parameters investigated in this study, a larger analysis of the effect of HSV-2 infection on foreskin T-cell populations²⁹ (which included a subset of the men described in the present work) previously found that HSV-2 was associated with increased CCR5 expression on foreskin CD4 T cells, but not with any other immune parameters investigated.

HIV neutralization by foreskin-derived IgA

The ability of purified sub-preputial IgA to neutralize infection of activated peripheral blood mononuclear cells (PBMCs) by a primary clade C HIV isolate was then assessed by research personnel blinded to participant study group. Using a predefined cutoff of $\geq 67\%$ neutralization compared with the reference sample, IgA purified from sub-preputial swabs of 9/18 (50%) HESN men was able to inhibit HIV infection of activated PBMC, whereas IgA from only 4/37 (10.8%) unexposed controls had this neutralizing capacity (**Figure 1**; prevalence risk ratio: 4.63; 95% confidence interval: 3.00–6.26%; Fisher’s exact $P = 0.002$). The absolute quantity of IgA in HESN samples was similar to that in controls (2,146 pg ml⁻¹ in controls vs. 1,649 pg ml⁻¹ in HESN, $P = 0.9$), and a sensitivity analysis using an increased cutoff of $\geq 90\%$ neutralization yielded similar results (neutralization seen in 9/18 HESN men vs. 2/37 control men, $P < 0.001$). Within the HESN group, IgA neutralization capacity did not correlate with the quantity of IgA, female partner viral load, length of time of HIV exposure, or the presence of HIV-specific CD8 T cells in his blood or foreskin. The presence of HIV-neutralizing IgA also did not correlate with HSV-2 status or concurrent extramarital relationships (data not shown).

Preputial levels of soluble innate immune factors and cytokines

Levels of innate antimicrobial peptides were quantified in the IgA-depleted fraction of sub-preputial swab eluate. Levels of the innate antimicrobial peptides Trappin2/Elafin, HNP1–3, HBD2, and SLPI are shown in **Figure 2**. The α -defensins HNP1–3 were present at a significantly higher level in swabs taken from the sub-preputial space of HESN men compared with controls (3,027 pg ml⁻¹ vs. 1,795 pg ml⁻¹; adjusted $P = 0.011$); among which HESN men correlated with the presence of neutralizing IgA (correlation coefficient 0.503, $P = 0.033$) but not partner viral load or length of HIV exposure. To ensure that IgA neutralization was not a result of HNP1–3, IgA fractions were also analyzed for the presence of HNP1–3: no HNP1–3 was detected in any IgA fractions (data not shown). Levels of Trappin2/Elafin, HBD2, and SLPI were similar between HESN men and unexposed controls.

Additionally, levels of cytokines and chemokines were assayed in a separate aliquot of undiluted sub-preputial swab samples (**Table 2**). IL-8 was present at a level that could be quantified in the majority of men; however, the median IL-8 levels did not differ significantly between HESN and control men (33.7 vs. 29.8 pg ml⁻¹ in HESN vs. control men, $P = 0.40$). MCP-1, monokine induced by γ -interferon (MIG), and

Table 1 Behavioral and demographic characteristics of participants

	HESN (<i>n</i> = 20)	Unexposed (<i>n</i> = 57)	Sig.
<i>Age (years)</i>			
Man	33 (23–53)	34 (22–51)	0.419
Woman	29 (20–41)	29 (19–49)	0.819
HSV-2 serology	14/20 (70.0%)	17/54 (31.5%)	0.004
Partner viral load (copies per ml)	5,589 (42–165,288)	n/a	
Partner CD4 count (cells per mm ³)	553 (295–1,592)	1,152 (492–2,019)	<0.001
Length of HIV exposure (years)	5 (0.5–15)	n/a	
<i>Condom use (%)</i>			
Always	1/20 (5.0%)	0/57 (0.0%)	0.114
Sometimes	5/20 (25.0%)	9/57 (15.8%)	
Not using	14/20 (70.0%)	48/57 (84.2%)	
<i>Sexual partners in past year</i>			
Single	15/20 (75.0%)	49/57 (86.0%)	0.304
Multiple	5/20 (25.0%)	8/57 (14.0%)	
Concurrent sexual partners (%)	3/20 (15.0%)	0/57 (0.0%)	0.016

Abbreviations: HESN, HIV-exposed but seronegative; HIV, human immunodeficiency virus; HSV-2, herpes simplex virus 2.




Figure 1 The ability of IgA isolated from the foreskin to neutralize human immunodeficiency virus (HIV). IgA was purified from foreskin secretions and incubated with a primary clade C viral isolate, which was subsequently challenged with peripheral blood mononuclear cells (PBMCs). The ability of IgA-treated virus to infect PBMCs was measured through p24 production. Capacity to neutralization of HIV was defined as 67% less p24 production compared with reference sample. The proportion of men in each group with HIV-neutralizing IgA is shown (HIV-exposed but seronegative (HESN) *n* = 18; Controls *n* = 37).

RANTES were present in < 50% of HESN men, and therefore the frequency of detection of these cytokines, as opposed to the concentration of analyte, was compared between groups. There were no HESN-associated differences in the frequency of detection of MCP-1 (42.1 vs. 50.9% of HESN vs. control men, *P* = 0.6), MIG (47.4 vs. 54.5%, *P* = 0.6), or RANTES (21.1 vs. 10.5%, *P* = 0.3). IL-1 α , macrophage-derived chemokine (MDC), and MIP-3 α were not detected in sub-preputial swabs. No HSV-2 associated differences in levels of cytokines, chemokines, and soluble innate factors were observed.




Figure 2 Levels of soluble innate immune proteins in foreskin secretions. Human immunodeficiency virus (HIV)-exposed but seronegative (HESN) (hatched bars) and unexposed control men (open bars). Sub-preputial swabs collected before surgery were assayed for levels of soluble innate immune proteins by ELISA. Median concentration (with range) of innate peptide in 1 ml collection volume is displayed (HESN *n* = 18; Controls *n* = 37). HBD2, human β -defensin 2; HNP1–3, human neutrophil peptides 1–3; SLPI, secretory leukocyte protease inhibitor.

T-cell subset density and relative proportions in the foreskin

The proportions of T-cell subsets in the blood and foreskin were assessed by flow cytometry, and the average tissue density of foreskin T-cell subsets was calculated by combining these proportions with immunohistochemical determination of CD3 T-cell density per mm² of tissue. The proportion of T cells expressing CD4 or CD8 did not differ between HESN men and unexposed controls (54.1 vs. 51.3% and 32.7 vs. 34.8% of T cells, respectively; n.s.). However, HESN men had a significantly

Table 2 Chemokine and cytokine levels in sub-preputial swabs

	LLOQ (pg ml ⁻¹)	HESN (n = 19)		Unexposed controls (n = 57)		Sig. ^a
		Frequency of detection (%)	Median (pg ml ⁻¹)	Frequency of detection (%)	Median (pg ml ⁻¹)	
IL-1 α	10.3	0 (0.0%)	—	0 (0.0%)	—	—
IL-8	1.5	18 (94.7%)	33.73	52 (91.2%)	29.84	0.40
MCP-1	0.6	8 (42.1%)	—	29 (50.9%)	0.69	0.60
MDC	1,250.0	0 (0.0%)	—	0 (0.0%)	—	—
MIG	0.3	9 (47.4%)	—	31 (54.4%)	0.34	0.61
MIP-3 α	46.2	0 (0.0%)	—	0 (0.0%)	—	—
RANTES	3.0	4 (21.1%)	—	6 (10.5%)	—	0.26

Abbreviations: HESN, HIV-exposed but seronegative; IL-1 α , interleukin-1 α ; LLOQ, lower limit of quantification; MCP-1, monocyte chemoattractant protein-1; MDC, macrophage-derived chemokine; MIG, monokine induced by γ -interferon; MIP-3 α , macrophage inflammatory protein-1 α .

^aIL-8 medians compared between groups using Mann-Whitney *U* test, else frequency of detection was compared using Fisher's exact test.

higher density of CD3 T cells per mm² of tissue after controlling for HSV-2 serostatus (151.9 vs. 69.9 cells per mm², adjusted $P=0.018$, **Figure 3c**), and therefore had higher absolute numbers of both CD4 and CD8 T cells per mm² of foreskin tissue (84.6 vs. 31.3 cells per mm², $P=0.022$; 45.6 vs. 22.7 cells per mm², $P=0.013$; **Figure 3c**). Density of foreskin T cells did not correlate with partner viral load.

Phenotype and function of foreskin T-cell subsets

Flow cytometry was used to further characterize the proportion of CD4 T cells classified as Th17 cells (production of IL-17 α upon stimulation), T-regulatory cells (Tregs; co-expression of CD25 and FoxP3), and expressing the HIV co-receptor CCR5 (representative plots of foreskin staining shown in **Figure 4a,d**). Compared with unexposed controls, HESN men had a decreased proportion of Th17 cells in both the blood and the foreskin (2.6 vs. 3.8% of blood CD4 T cells, $P=0.042$; 6.1 vs. 8.0% of foreskin CD4 T cells, $P=0.007$; **Figure 4e**), but a similar proportion of Tregs (4.1 vs. 3.7% of blood CD4 T cells, n.s.; 2.9 vs. 3.7% of foreskin CD4 T cells, n.s.) and of CCR5⁺ CD4 T cells (7.8 vs. 8.7% of blood CD4 T cells, n.s.; 44.3 vs. 40.0% of foreskin CD4 T cells, n.s.; **Figure 4b**). This decreased relative abundance of Th17 cells did not correlate with partner viral load. Given the higher overall tissue density of T cells in the HESN foreskin, this translated into a similar absolute number of Th17 cells per mm² in HESN men (4.9 vs. 2.7 cells per mm², n.s.; **Figure 4f**), and an increased absolute number of CCR5⁺ CD4 T cells per mm² (41.5 vs. 12.5, $P=0.023$; **Figure 4c**).

Production of the cytokines IFN γ and TNF α by foreskin and blood T cells after phorbol-12-myristate-13-acetate (PMA)-ionomycin stimulation was assessed by intracellular cytokine production (representative plots of foreskin staining shown in **Figure 5a,f**), with CD8⁻ T cells used as a proxy for CD4 T cells. A decreased proportion of HESN CD8 and CD4 T cells produced TNF α in both the blood (CD8 T cells, 29.4 vs. 38.8%, $P=0.032$; CD4 T cells, 31.4 vs. 43.2%, $P=0.007$) and the foreskin (CD8 T cells, 36.9 vs. 45.7%, $P=0.004$; CD4 T cells, 34.3 vs. 41.8%, $P=0.037$; **Figure 5d,i**). This decrease did not

correlate with partner viral load. The absolute number of TNF α -producing CD8 or CD4 T cells was not statistically different in HESN and unexposed control foreskin tissue (15.9 vs. 9.1 CD8 T cells per mm², **Figure 5e**, n.s.; 18.3 vs. 12.7, **Figure 5j**, n.s.). The proportion of CD8 and CD4 T cells producing IFN γ was similar between groups (38.1 vs. 41.5% PBMC CD8, n.s.; 43.2 vs. 47.6% foreskin CD8, n.s., **Figure 5b**; 12.8 vs. 16.5% PBMC CD4, n.s.; 17.5 vs. 23.7% foreskin CD4, n.s., **Figure 5g**, n.s.), and so the increased overall T-cell density in the HESN foreskin translated into a higher absolute number of IFN γ -producing CD8 T cells (19.7 vs. 8.3 cells per mm², $P=0.011$; **Figure 5c**), but not CD4 T cells (11.7 vs. 6.94 cells per mm², n.s.; **Figure 5h**).

HIV-specific T-cell responses in the foreskin

Blood and foreskin cell suspensions were stimulated with a pool of pre-defined, optimized CD8 T-cell peptide epitopes (see Methods, above). To be considered a positive HIV-specific response: (i) $\geq 0.3\%$ of CD8 T cells had to produce either TNF α or IFN γ in response to peptide stimulation (background subtracted) and (ii) cytokine production in response to peptides had to exceed background cytokine production by at least threefold. HIV-specific CD8 T-cell responses were observed in both the blood and the foreskin of a minority of participants (representative plot, **Figure 6a**), but there was no significant difference in the frequency of an HIV-specific response between HESN men and unexposed controls (blood, 5/20 (25.0%) vs. 7/57 (12.3%); foreskin, 4/20 (20.0%) vs. 8/57 (14.0%); both $P>0.2$, **Figure 6b**). Among participants with an HIV-specific response, the magnitude of that response was also similar in HESN men and controls for both the blood (mean % CD8 T cells producing TNF α among responding HESN men = 1.51 vs. 1.47% in unexposed controls, n.s.; mean % producing IFN γ = 0.71 vs. 0.37%, n.s.) and the foreskin, where only IFN γ responses were observed (0.37 vs. 1.02%, n.s.). The presence of HIV-specific responses in HESN men did not correlate with partner viral load or length of time of exposure to HIV, and did not correlate with other immune parameters found to be associated with HESN status (data not shown).




Figure 3 T-cell subsets in the blood and foreskin. Human immunodeficiency virus (HIV)-exposed but seronegative (HESN) (hatched bars) and unexposed control men (open bars). The proportion of CD3⁺ T cells expressing either CD4 or CD8 was measured on peripheral blood mononuclear cells (PBMCs) and foreskin cells using flow cytometry (**b**); representative flow cytometry plots showing the gating strategy for foreskin cells are shown in panel **a**. Proportions of T-cell subsets were normalized to the number of CD3 T cells per mm² of foreskin tissue (obtained using immunohistochemistry (IHC)) to obtain absolute numbers of each cell type (**c**) (HESN $n=20$, Controls $n=57$).

DISCUSSION

Natural susceptibility to HIV is heterogeneous, and elucidation of the mucosal immune correlates of reduced HIV susceptibility at sites of sexual exposure may provide important lessons for the HIV vaccine and microbicide fields. We combined epidemiological data collected through the Rakai Community Cohort Study with blinded immune studies of sub-preputial swabs and foreskin tissues to explore the immune correlates of HIV exposure without infection in the foreskin. We found secretions from the HESN foreskin to be enriched for α -defensins and HIV-neutralizing IgA. HESN foreskin tissue had an increased overall density of CD3⁺ T cells, but these T cells contained disproportionately fewer Th17 cells and produced less of the pro-inflammatory cytokine TNF α . We did not find that HIV-specific T-cell responses were associated with the HESN phenotype.

Our observation that HESN men were more likely to have IgA with the capacity to neutralize HIV is consistent with numerous previous reports, including studies in diverse HESN populations examining several mucosal sites.^{12–14,30–34} While the presence of IgA with the ability to neutralize HIV in HESN populations is well established, the *specificity* of this IgA remains unknown.³⁵ Detection of HIV-specific IgA by a binding assay such as an ELISA or western blotting is rare,^{36,37} and it is of note that the presence of HIV-neutralizing IgA did not correlate with foreskin HIV-specific CD8 T cells in this

study. It may be that the target of this IgA is not HIV itself, but a host factor involved in HIV binding, such as CCR5, a lectin receptor,³⁸ or the integrin $\alpha_4\beta_7$.³⁹ Determining the target, mechanism of action, and source of this frequently observed neutralizing IgA should be a research priority.

While the sub-preputial space contained significant levels of several innate immune factors and cytokines, only the α -defensins HNP1–3 were enriched in HESN sub-preputial swabs. Our group previously found that both HNP1–3 and IgA in female genital secretions of Kenyan sex workers were correlated with *in vitro* HIV neutralization.³ However, while HIV-neutralizing IgA was prospectively associated with HIV protection, increased α -defensins were associated with the presence of other genital co-infections as well as with an unexpected increase in the risk of HIV acquisition.³ The latter finding may reflect the T-cell chemoattractant properties of some antiviral innate factors and cytokines, as demonstrated by the association of vaginal RANTES levels with increased mucosal CD4⁺ target cells *in vivo*,¹¹ and emphasizes that *ex vivo* antiviral activity does not always predict *in vivo* protection against HIV.

We found that HESN men had an increased density of CD3⁺ T cells per mm² in their foreskin tissue, independently of their HSV-2 serostatus. While this was unexpected, increased numbers of cervical T cells have been observed previously in HESN female commercial sex workers.¹¹ Despite having an




Figure 4 CD4 T-cell subsets in the blood and the foreskin. Human immunodeficiency virus (HIV)-exposed but seronegative (HESN) (hatched bars) and unexposed control men (open bars). CCR5 expression was measured on peripheral blood mononuclear cells (PBMCs) and foreskin CD4 T cells using flow cytometry (representative foreskin plot in panel a). Th17 cells were identified by production of IL-17 α by CD4 T cells in response to stimulation with phorbol-12-myristate-13-acetate (PMA) and ionomycin (representative foreskin plot in panel d). Summary data of the proportion of CCR5 + CD4 T cells and Th17 cells in the blood and the foreskin are shown in panels b and e. Absolute numbers of cells, obtained by immunohistochemistry (IHC) of CD3, are shown in panels c and f (HESN $n=20$, Controls $n=57$).

increased overall number of CD3⁺ T cells per mm² of foreskin tissue, a smaller proportion of these T cells were Th17 cells or had the capacity to produce the pro-inflammatory cytokine TNF α . Studies in an SIV-rhesus macaque model have shown that initial infection in the female genital tract begins with a small founder population of infected T cells which grows through the recruitment of new, activated target cells driven by local inflammation.⁴⁰ Levels of susceptible target cells and local inflammation may therefore be a determinant in individual susceptibility to HIV. Th17 cells have been shown to be highly HIV susceptible *in vitro*^{41,42} and to be selectively depleted during early HIV infection,⁴¹ while TNF α increases HIV replication in a paracrine manner and is produced by activated T cells that are more permissive to HIV infection⁴³ and replication.⁴⁴ TNF α has also been shown to recruit CD4 T cells to foreskin tissue *ex vivo*,⁴⁵ and to activate dendritic cells, which may pass HIV to susceptible CD4 T cells through viral synapses.^{38,46} Therefore, decreased production of TNF α and decreased proportion of Th17 cells in the HESN foreskin may inhibit the establishment of a founder population of infected cells after HIV exposure.

A decreased relative abundance of highly susceptible cell populations in conjunction with an increased overall number of T cells implies that there is an increased abundance of other T-cell subsets. Further elucidation of these T-cell populations in the HESN foreskin using multiparameter flow cytometry, as

opposed to the 4-color flow system available at our field site, should be a priority in future studies. This would also allow for characterization of other cell types that have been newly identified as important in HIV susceptibility, such as Th22 cells⁴⁷ or cells expressing the gp120-binding integrin $\alpha_4\beta_7$.³⁹ Furthermore, the position of susceptible target cells within the foreskin may also be very relevant to HIV susceptibility, particularly their depth below the epithelial surface and/or proximity to other immune cell subsets. Ideally, future studies should identify exclusive surface markers for relevant T-cell subsets, which would permit immunohistochemical analysis of these parameters.

It is important to note that the sexual behaviour of HESN individuals is, by definition, different from that of low risk men. Therefore, cross-sectional studies of HESN genital immunology cannot distinguish which unique immune characteristics (if any) are protective against HIV, and which are related to increased sexual risk and may actually enhance susceptibility. Furthermore, while prospective studies of HIV acquisition would seem to be a way to address this issue, a drawback of using tissues obtained during male circumcision is that prospective studies of HIV acquisition in the foreskin then become impossible (as the foreskin is absent in future sexual exposures). Therefore, animal models and/or improved *ex vivo* explant models of foreskin HIV infection may be useful ways to further characterize the direction of causation of the HESN immune associations that we have described.




Figure 5 Inflammatory cytokine production by CD8 (a–e) and CD4 (f–j) T cells. Human immunodeficiency virus (HIV)-exposed but seronegative (HESN) (hatched bars) and unexposed control men (open bars). T cells isolated from foreskin tissue were challenged with phorbol-12-myristate-13-acetate (PMA) and ionomycin and subsequent tumor necrosis factor α (TNF α) and interferon- γ (IFN γ) production by either CD8 + T cells or CD8 – T cells (a proxy for CD4 T cells) was measured by flow cytometry (representative plots shown for CD8 (a) and CD4 T cells (f)). Summary data of the proportion of CD8 T cells producing TNF α or IFN γ are shown in panels b and d, respectively. Absolute numbers of each cell type, obtained through CD3 immunohistochemistry (IHC), are shown in panels c and e. Similarly, proportions of CD4 T cells producing TNF α or IFN γ are shown in (g) and (i), and absolute numbers of each cell type are shown in panels h and j (HESN $n=20$, Controls $n=57$). PBMC, peripheral blood mononuclear cell.

In summary, we have combined epidemiology and mucosal immunology to define the unique immunological features of foreskins from men from Rakai, Uganda who are regularly

exposed to HIV but have remained uninfected. We find that the foreskin of HESN men is characterized by increased overall T-cell density in the context of reduced Th17 frequencies and




Figure 6 Human immunodeficiency virus (HIV)-specific CD8 T-cell responses in the foreskin. CD8 T cells isolated from foreskin tissue were challenged with a pool of cross-clade HIV peptides previously shown to be highly antigenic in an East African population. **(a)** Tumor necrosis factor α (TNF α) and interferon- γ (IFN γ) production by CD8 T cells was measured by flow cytometry. **(b)** Frequency of response for HIV-exposed but seronegative (HESN) and unexposed control men. An HIV-specific response was defined as cytokine production three times greater than observed in unstimulated cells and a minimum of 0.3% (HESN $n=20$, Controls $n=57$). PBMC, peripheral blood mononuclear cell.

reduced pro-inflammatory cytokine production, and by the presence of HIV-neutralizing IgA and elevated α -defensin levels in foreskin secretions. The ability of these immune parameters, either separately or in combination, to protect against HIV acquisition in the foreskin merits investigation in future research studies.

METHODS

Study participants. Participants consisted of 77 heterosexual couples enrolled in a broader study of foreskin immunology.^{27,29} Participants were recruited from an established community cohort in Rakai, Uganda,²⁸ in which the HIV-seronegative male partner had elected to undergo adult male circumcision for HIV prevention. HESN men were HIV seronegative and in a stable relationship with an anti-retroviral therapy-naïve, HIV-seropositive female who had a detectable HIV plasma viral load, and reported inconsistent or no condom use with this female partner despite risk-reduction counseling and the provision of free condoms. Unexposed control men were HIV seronegative and in a monogamous relationship with an HIV-seronegative woman. All participants provided written informed consent, and formal ethical approval was obtained at the University of Toronto, the Uganda Virus Research Institute's Scientific and Ethical Committee, Karolinska Institutet and Western IRB (Olympia, WA).

Sample collection and diagnostic testing. Each partner within the couple completed a behavioral questionnaire before sample collection/surgery. Women provided 8 ml of venous blood. Men underwent a physical examination before surgery, and circumcision was deferred until after treatment if urethral discharge or clinically apparent genital ulceration was present; 16 ml of whole blood and a swab from the sub-preputial space were then collected before surgery. A single sub-preputial swab was collected from each participant immediately before surgery using a FLOQswab (COPAN Diagnostics, Murrieta, CA) pre-moistened in sterile phosphate-buffered saline and rolled once around the coronal sulcus and once down the frenulum. Swabs were collected by the same medical officers' throughout the study, and care was taken to collect each swab in a consistent manner. Swabs were then resuspended in 1 ml of AMPLICOR STD Specimen Transport Kit medium (Roche Diagnostic Systems, Branchburg, NJ) and stored at 4 °C until division into two aliquots (one for cytokine detection and other for IgA/innate factor analysis), which were stored at -80 °C. Foreskin tissue was processed immediately upon surgical excision in a room adjoining the surgical suite, with two sections snap-frozen into

cryomolds in Optimal Cutting Temperature compound (Fisher Scientific, Toronto, Ontario, Canada) for immunohistochemistry (IHC), and one large section collected for T-cell isolation. All foreskin tissues were labeled with a unique identifier and provided to research personnel blinded to participant study group for subsequent processing and immune analysis.

The HIV infection status of both partners was confirmed using two HIV ELISAs (Murex HIV-1.2.O; Abbott, Abbott Park, IL; and Vironistika HIV Uni-Form II plus O Mircoelisa System; bioMerieux; Marcy l'Etoile, France). Discordant results were confirmed by western blotting (GS HIV-1 Western Blot; Bio-Rad; Hercules, CA). All participants were also screened for acute HIV infection using real-time PCR. RNA was extracted from plasma samples using the Abbott Sample Preparation System, and amplification was performed using the Real Time HIV-1 Amplification Reagent Kit (Abbott) and run on the M2000rt (Abbott) with a lower limit of detection of 40 c.p.s. ml⁻¹. CD4 counts were performed using Tritest reagent in combination with Trucount Tubes and were analyzed on a FACSCalibur platform (BD Biosciences, San Jose, CA). HSV-2 infection status was determined by ELISA (Herpes Simplex Type 2 IgG ELISA; Kalon Biological, Guildford, UK), as previously validated in Rakai.⁴⁸

T-cell isolation from the foreskin and blood. T-cell isolation from foreskin tissues and blood was initiated within 15 min of surgery, as previously described.²⁷ Briefly, tissue was disrupted by a combination of mechanical and enzymatic digestion with 1.0 ml of 500 U ml⁻¹ Collagenase Type I (Gibco, Invitrogen; Carlsbad, CA) and 42.5 U ml⁻¹ of DNase (Invitrogen). The resulting cell suspension was filtered through a 100- μ m cell strainer (BD Biosciences, Franklin Lakes, NJ) to remove any remaining undigested tissue. Filtered cells were allowed to rest under normal growth conditions (37 °C, 5% CO₂, humidified atmosphere) for 3–7 h. PBMCs were isolated by density gradient centrifugation (Ficoll-Paque Plus; Amersham Biosciences, Uppsala, Sweden).

Characterization of T-cell subsets. Both PBMC and foreskin cell counts were determined by trypan blue exclusion. 1×10^6 PBMCs and 10–20 $\times 10^6$ foreskin cells (depending on yield) were plated in 500 μ l culture medium and stimulated for 9 h at 37 °C in the presence of 5 μ g ml⁻¹ Brefeldin A (GolgiPlug; BD Biosciences), with either: 1 ng ml⁻¹ PMA and 1 μ g ml⁻¹ ionomycin (both from Sigma, St Louis, MO); or 102 μ g ml⁻¹ of a pool of 51 HIV peptide epitopes (9–11 amino acids long, JPT Peptide Technologies, Berlin, Germany) previously found by our group to be highly antigenic in an East African population;⁴⁹ or

vehicle (0.1% dimethyl sulfoxide). After stimulation, samples were washed with cold 2% fetal bovine serum in phosphate-buffered saline and stained with fluorochrome-labeled monoclonal antibodies specific for CD3 (UCHT1), CD4 (RPA-T4), CD8 (SK1), CCR5 (2D7/CCR5), and CD25 (M-A251; all from BD Biosciences). Samples for intracellular staining were permeabilized using either the eBioscience fixation/permeabilization solution for Treg identification (eBiosciences, San Diego, CA) or the BD Cytotfix/Cytoperm solution (BD Biosciences) for other assays. Cells were then stained with fluorochrome-labeled monoclonal antibodies specific for combinations of the following intracellular cytokines/transcription factors: TNF α (MAB11; BD Biosciences), IFN γ (B27; BD Biosciences), IL17a (eBio64DEC17; eBioscience), IL22 (22URTI; eBioscience), and FoxP3 (PCH101; eBioscience). Samples were acquired using a FACSCalibur flow cytometer (BD Biosciences). Gating was performed as previously described.²⁷

Measuring CD3 density by IHC. To translate flow-derived cell proportions into an absolute tissue density of foreskin T cells, two sections of foreskin were collected from each participant and IHC was performed. Optimal Cutting Temperature cryopreserved tissues were sectioned to 8 μm , fixed in 2% formaldehyde, and frozen for batch staining. For CD3 staining, frozen sections were thawed and air dried at room temperature. Endogenous peroxidase and biotin activities were blocked using 0.3% hydrogen peroxide and avidin/biotin blocking kit (Vector Labs, Burlingame, CA), respectively, followed by 10% normal goat serum. Sections were then incubated with rabbit anti-human CD3 antibody (DAKO, Burlingame, CA; Vector Labs), followed by biotin-labeled goat anti-rabbit secondary and Alkaline Phosphatase Streptavidin Labeling Reagent (all from Vector Labs). Color development was performed with freshly prepared Alkaline Phosphatase Substrate Kit Vector Red (Vector Labs). Finally, sections were counterstained lightly with Mayer's Hematoxylin, dehydrated in alcohols, cleared in xylene, and mounted in Permount (Fisher Scientific). The number of CD3⁺ T cells per mm² of tissue for each patient was derived from the average of two tissue sections taken from distal locations on the foreskin. A median of 6.10 mm² of foreskin tissue was analyzed by IHC per patient. Whole sections were scanned at 0.5 μm per pixel using the TissueScope 4000 (Huron Technologies, Waterloo, Canada). Image analysis software (Definiens, München, Germany) was used to delineate the apical edge of the epidermis and create fields of view of the entire length of each section to a depth of 300 μm (excluding artifacts or folds, see **Supplementary Data** online). CD3 cells in each field of view were manually counted by an investigator blinded to group status. A CD3-positive cell was defined as nuclear hematoxylin staining overlapping with, or directly adjacent to, Vector Red staining.

IgA purification and PBMC neutralization assays. Neutralizing IgA activity was assessed in a subset of samples (18 HESN men and 37 unexposed controls) where samples were available. One aliquot of sub-preputial swab (500 μl) was thawed and centrifuged at 1,500 r.p.m. (5 min, 4 °C) to remove cellular debris. IgA was purified as previously described.³² Briefly, 400 μl undiluted swab solution was added to 200 μl Jacalin/agarose beads (Vector Labs), mixed for 2 h at 4 °C, and centrifuged to separate the IgA-depleted fraction (stored at -80 °C for innate factor analysis). Jacalin/agarose beads were thoroughly washed with phosphate-buffered saline pH 7.4, and bound IgA was eluted overnight at room temperature by adding 500 μl 0.8 M D-galactose pH 7.5. The supernatant (purified IgA) was collected, diluted 1:2 with RPMI-1640 medium (Invitrogen AB, Lidingö, Sweden) and stored at -80 °C. HIV neutralization assays were performed according to a predefined protocol and neutralization cutoff.¹⁴ R5 tropic primary isolates (clade C: ZA009, obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH) were collected from PBMC stimulated with phytohemagglutinin and IL-2 (both from Sigma-Aldrich Sweden AB, Stockholm, Sweden). The TCID50 was determined and supernatants were aliquoted and stored

at -80 °C. Since the TCID50 may differ between PBMC donors, three viral dilutions were used in each assay. IgA fractions were diluted 1:2 with RPMI-1640 medium (Invitrogen AB) and 75 μl of this diluted sample was incubated with 75 μl of each virus dilution (in duplicate) for 1 h at 37 °C to allow for viral neutralization. Virus was mixed with 1×10^5 phytohemagglutinin-stimulated mixed PBMCs from 2 to 3 donors; after 24 h incubation at 37 °C, PBMCs were washed and cultured for 6 days in 200 μl of fresh RPMI-1640 medium supplemented with bovine serum albumin and IL-2, with half of the medium replaced on day 3. Supernatants were collected on day 6 for analysis of virus production with a p24 antigen ELISA (Vironostika HIV-1 Antigen; Electra-Box Diagnostica AB, Stockholm, Sweden). Percent neutralization was defined as the reduction in p24 production compared with a reference sample (created by pooling IgA from five unexposed control men). However, there is a significant inter-assay variability in the quantity of p24 antigen produced as a result of PBMC donor variability. We therefore treated IgA neutralization as a binary outcome, where successful neutralization was defined as $\geq 67\%$ neutralization. A cutoff of $\geq 67\%$ provides robust reproducibility of successful neutralization,¹³ has been shown to correlate prospectively with protection from infection.¹⁴ Positive control samples (HIV IgG-positive serum) were included in each assay. Samples that did not have consistent absence/presence of neutralization in all three viral dilutions were re-tested until a consensus was achieved.

Innate factor analysis. Trappin/Elafin, HNP1-3, HBD2, and SLPI were quantified in IgA-depleted fractions of sub-preputial swabs. Commercial ELISA kits were used according to the manufacturers' protocols as follows (additional dilutions in parentheses): Trappin/Elafin (1:10), α -defensins HNP1-3 (1:10) (all from HyCult Biotechnology, Uden, The Netherlands), β -defensins HBD2 (1:10-1:100) (Phoenix Pharmaceuticals, Burlingame, CA), and SLPI (1:5-1:100) (RD Systems Europe, Abingdon Oxon, UK).

Cytokine and chemokine analysis of sub-preputial swabs. The second 500 μl aliquot of sub-preputial swab was assayed for cytokine levels using an electrochemiluminescent detection system. A custom Human Ultra-Sensitive 7-spot kit from Meso Scale Discovery (Rockville, MD) was utilized to assay the following cytokines and chemokines in the undiluted sub-preputial swabs: IL-1 α , IL-8, MCP-1, MDC, MIG, MIP-3 α , and RANTES. Plates were imaged using the Sector Imager 2400 A platform (Meso Scale Discovery). The manufacturer suggests determining the lower limit of quantification (LLOQ) for each analyte on a per-plate basis. However, due to the large number of samples analyzed in this study multiples were required and as a result of inter-run variability slightly different LLOQ values were obtained. For the purposes of this study, we set an overall study LLOQ at 75th quartile of all plate LLOQs. Sample measurements below the study LLOQ were imputed as the value of the LLOQ: IL-1 α = 10.3 pg ml⁻¹; IL-8 = 1.5 pg ml⁻¹; MCP-1 = 0.6 pg ml⁻¹; MDC = 1,250.0 pg ml⁻¹; MIG = 0.3 pg ml⁻¹; MIP-3 α = 46.2 pg ml⁻¹; and RANTES = 3.0 pg ml⁻¹. However, due to the low chemokine concentrations in sub-preputial swabs, only levels of IL-8 were quantifiable in > 50% of men in both groups, and as a result cytokines other than IL-8 were treated as a binary outcome of either "detectable" or "undetectable".

Statistical analysis. All immune assays were performed by research personnel blinded to participant study group; immune data files were cleaned and finalized before study group linkage. Innate factors, chemokines, cytokines, and T-cell populations were compared between HESN and unexposed controls by Mann-Whitney *U*-test. Associations between demographic factors and immunological parameters were tested by Spearman's correlation coefficient. Demographic variables found to be associated with HESN status (HSV-2 status and concurrent sexual partners) were controlled for by multivariate general linear regression and adjusted *P*-values are reported. Proportions of

men with HIV-specific IgA and CD8 T-cell responses were compared by Fisher's exact test. Statistical tests were run using SPSS v.19.0 for Mac (IBM; New York, NY). Flow cytometry data were analyzed in FlowJo v.9.5.2 (Treestar, Ashland, OR) and Excel (Microsoft, Redmond, WA) before statistical testing.

SUPPLEMENTARY MATERIAL is linked to the online version of the paper at <http://www.nature.com/mi>

ACKNOWLEDGMENTS

We would like to acknowledge STTARR at the Toronto MaRS Discovery District for assistance with CD3 image analysis and Mariethe Ehnlund at the Karolinska Institute for technical assistance. Funding was provided by the Bill and Melinda Gates Foundation, grant number 22006.03, and R01AI087409-01A1, U01AI51171, and 1U01AI075115-01A1 from the National Institutes of Health. The study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

DISCLOSURE

The authors declare no conflict of interest.

© 2014 Society for Mucosal Immunology

REFERENCES

- Hladik, F. & McElrath, M.J. Setting the stage: host invasion by HIV. *Nat. Rev. Immunol.* **8**, 447–457 (2008).
- Levinson, P. *et al.* HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships. *PLoS ONE* **7**, e31996 (2012).
- Levinson, P. *et al.* Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. *AIDS* **23**, 309–317 (2009).
- Quinones-Mateu, M.E. *et al.* Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. *AIDS* **17**, F39–F48 (2003).
- Zapata, W. *et al.* Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals. *Curr. HIV Res.* **6**, 531–538 (2008).
- Lajoie, J. *et al.* A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers. *Mucosal Immunol.* **5**, 277–287 (2012).
- Burgener, A. *et al.* Salivary basic proline-rich proteins are elevated in HIV-exposed seronegative men who have sex with men. *AIDS* **26**, 1857–1867 (2012).
- Iqbal, S.M. *et al.* Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. *AIDS* **23**, 1669–1677 (2009).
- Hirbod, T. *et al.* Upregulation of interferon-alpha and RANTES in the cervix of HIV-1-seronegative women with high-risk behavior. *J. Acquir. Immune Defic. Syndr.* **43**, 137–143 (2006).
- Hirbod, T. *et al.* HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals. *Curr. HIV Res.* **6**, 28–33 (2008).
- Iqbal, S.M. *et al.* Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. *J. Infect. Dis.* **192**, 728–738 (2005).
- Hasselrot, K. *et al.* Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. *AIDS* **23**, 329–333 (2009).
- Choi, R.Y. *et al.* Cervicovaginal HIV-1 neutralizing IgA detected among HIV-1-exposed seronegative female partners in HIV-1-discordant Kenyan couples. *AIDS* **26**, 2155–2163 (2012).
- Hirbod, T. *et al.* HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. *AIDS* **22**, 727–735 (2008).
- Kaul, R. *et al.* Genital levels of soluble immune factors with anti-HIV activity may correlate with increased HIV susceptibility. *AIDS* **22**, 2049–2051 (2008).
- Zhou, Z. *et al.* HIV-1 efficient entry in inner foreskin is mediated by elevated CCL5/RANTES that recruits T cells and fuels conjugate formation with Langerhans cells. *PLoS Pathog.* **7**, e1002100 (2011).
- Card, Catherine M. *et al.* Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4+ CD25+ FOXP3+ regulatory T cells. *J. Infect. Dis.* **199**, 1318–1322 (2009).
- Legrand, F.A. *et al.* Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. *PLoS ONE* **1**, e102 (2006).
- Bégaud, E. *et al.* Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. *Retrovirology* **3**, 35 (2006).
- Koning, F.A. *et al.* Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. *J. Immunol.* **175**, 6117–6122 (2005).
- Camara, M. *et al.* Low-level CD4+ T cell activation in HIV-exposed seronegative subjects: influence of gender and condom use. *J. Infect. Dis.* **201**, 835–842 (2010).
- Chege, D. *et al.* Blunted IL17/IL22 and pro-inflammatory cytokine responses in the genital tract and blood of HIV-exposed, seronegative female sex workers in Kenya. *PLoS ONE* **7**, e43670 (2012).
- McLaren, P.J. *et al.* HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. *J. Infect. Dis.* **202** (Suppl 3), S339–S344 (2010).
- Auvert, B. *et al.* Randomized, controlled intervention trial of male circumcision for reduction of HIV Infection risk: the ANRS 1265 trial. *PLoS Med.* **2**, e298 (2005).
- Bailey, R. *et al.* Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. *Lancet* **369**, 643–656 (2007).
- Gray, R.H. *et al.* Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. *Lancet* **369**, 657–666 (2007).
- Prodger, J.L. *et al.* Foreskin T-cell subsets differ substantially from blood with respect to HIV co-receptor expression, inflammatory profile, and memory status. *Mucosal Immunol.* **5**, 121–128 (2012).
- Gray, R.H. *et al.* Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. *AIDS* **14**, 2371–2381 (2000).
- Prodger, J.L. *et al.* Impact of asymptomatic Herpes simplex virus-2 infection on T cell phenotype and function in the foreskin. *AIDS* **26**, 1319–1322 (2012).
- Beyrer, C. *et al.* Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. *J. Infect. Dis.* **179**, 59–67 (1999).
- Broliden, K. *et al.* Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. *Immunol. Lett.* **79**, 29–36 (2001).
- Devito, C. *et al.* Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. *AIDS* **14**, 1917–1920 (2000).
- Kaul, R. *et al.* HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. *AIDS* **13**, 23–29 (1999).
- Lo Caputo, S. *et al.* Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. *AIDS* **17**, 531–539 (2003).
- Hirbod, T., Broliden, K. & Kaul, R. Genital immunoglobulin A and HIV-1 protection: virus neutralization versus specificity. *AIDS* **22**, 2401–2402 (2008).
- Fiore, J.R. *et al.* Limited secretory-IgA response in cervicovaginal secretions from HIV-1 infected, but not high risk seronegative women: lack of correlation to genital viral shedding. *New Microbiol.* **23**, 85–92 (2000).
- Horton, R.E. *et al.* Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. *AIDS Res. Hum. Retroviruses* **25**, 83–92 (2009).
- Soderlund, J. *et al.* Plasma and mucosal fluid from HIV type 1-infected patients but not from HIV type 1-exposed uninfected subjects prevent HIV type 1-exposed DC from infecting other target cells. *AIDS Res. Hum. Retroviruses* **23**, 101–106 (2007).
- Cicala, C. *et al.* The integrin $\alpha 4\beta 7$ forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. *Proc. Natl Acad Sci* **106**, 20877–20882 (2009).
- Li, Q. *et al.* Glycerol monolaurate prevents mucosal SIV transmission. *Nature* **458**, 1034–1038 (2009).

41. Gosselin, A. *et al.* Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. *J. Immunol.* **184**, 1604–1616 (2010).
42. Monteiro, P. *et al.* Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin beta7. *J. Immunol.* **186**, 4618–4630 (2011).
43. Zhang, Z.Q. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. *Proc. Natl. Acad. Sci.* **101**, 5640–5645 (2004).
44. Jaspan, H.B. *et al.* Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. *J. Infect. Dis.* **204**, 1550–1556 (2011).
45. Fahrback, K.M., Barry, S.M., Anderson, M.R. & Hope, T.J. Enhanced cellular responses and environmental sampling within inner foreskin explants: implications for the foreskin's role in HIV transmission. *Mucosal Immunol.* **3**, 410–418 (2010).
46. Ganor, Y. *et al.* Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans–T cell conjugates. *Mucosal Immunol.* **3**, 506–522 (2010).
47. Kim, C.J. *et al.* A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. *Mucosal Immunol.* **5**, 670–680 (2012).
48. Gamiel, J.L. *et al.* Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda. *Clin. Vaccine Immunol.* **15**, 888–890 (2008).
49. Kaul, R. *et al.* New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. *Immunol. Lett.* **79**, 3–13 (2001).